AVIR — Atea Pharmaceuticals Share News
0.000.00%
Last trade - 00:00- $324.03m
- $104.56m
U.S. STOCKS ON THE MOVE-Atea Pharma, Microbot Medical, Krystal
Atea Pharma rises on buyout offer from Concentra
Brief: Tang Capital Partners, LP- Concentra Sent Acquisition Proposal To Atea Pharmaceuticals With Terms To Acquire All Of Its Outstanding Common Stock
Brief: Atea Pharmaceuticals Reports First Quarter 2023 Financial Results And Provides Business Update
Atea Pharmaceuticals Inc reports results for the quarter ended in March - Earnings Summary
Brief: Atea Pharmaceuticals posts Q1 net income USD -35.467 million
Atea Pharmaceuticals Inc expected to post a loss of 48 cents a share - Earnings Preview
Atea Pharma up on FDA's 'fast track' tag for COVID-19 drug
Brief: Atea Pharma to Present New Data Of Bemnifosbuvir For Treatment Of Covid-19 And Hepatitis C
Atea Pharmaceuticals Inc reports results for the quarter ended in December - Earnings Summary
Brief: Atea Pharmaceuticals Reports Fourth Quarter And Full Year 2022 Financial Results And Provides Business Update
Atea Pharmaceuticals Inc expected to post a loss of 45 cents a share - Earnings Preview
Brief: Atea Pharmaceuticals To Report Fourth Quarter And Full Year 2022 Financial Results And Provide Business Update On February 28, 2023
Brief: Atea Pharmaceuticals Highlights Strategic Priorities For 2023
Atea Pharma up on enrolling first patient in COVID trial
Brief: Atea Pharmaceuticals Dosed First Patient In Phase 3 Trial For Covid-19 Treatment
Atea Pharmaceuticals Inc reports results for the quarter ended in September - Earnings Summary
Brief: Atea Pharmaceuticals Reports Third Quarter 2022 Financial Results
Atea Pharmaceuticals Inc expected to post a loss of 44 cents a share - Earnings Preview